CASI Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference

ROCKVILLE, Md., Feb. 2, 2015 - CASI Pharmaceuticals, Inc. (Nasdaq: ENMD), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary commercial focus on China, announces that Ken K. Ren, Ph.D., CASI’s Chief Executive Officer, will be making a corporate presentation at the BIO CEO & Investor conference, to be held February 9-10 in New York City. Dr. Ren will present on February 9 at 8:00 a.m. Eastern time.

The presentation will be webcast live and a link will be available on the Company’s website at www.casipharmaceuticals.com and here. A webcast replay will be available beginning one hour after the conclusion of the live event, and will be available through May 10, 2015.

About CASI Pharmaceuticals, Inc.

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary commercial focus on China. CASI’s product pipeline includes exclusive rights to ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and Captisol-EnabledTM (propylene glycol-free) melphalan (CE melphalan) for greater China (including Taiwan, Hong Kong and Macau). CASI’s development pipeline also includes its proprietary drug candidate ENMD-2076, a selective angiogenic kinase inhibitor currently in multiple Phase 2 oncology studies, and 2ME2 (2-methoxyestradial) currently under reformulation development. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

ZEVALIN® and MARQIBO® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. Captisol-Enabled™ is the trademark property of its owner.